Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery

Heebeom Koo, Kyung Hyun Min, Sang Cheon Lee, Jae Hyung Park, Kinam Park, Seo Young Jeong, Kuiwon Choi, Ick Chan Kwon, Kwang Meyung Kim

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Enhanced drug-loading and therapeutic efficacies are highly essential properties for nanoparticles as tumor-targeting drug carriers. Herein, we developed the glycol chitosan nanoparticles with hydrotropic oligomers (HO-CNPs) as a new tumor targeting drug delivery system. For enhancing drug-loading efficiency of paclitaxel in drug carriers, hydrotropic 2-(4-(vinylbenzyloxy)-N, N-diethylnicotinamide) (VBODENA-COOH) oligomers, that were used for enhancing the aqueous solubility of paclitaxel, were directly conjugated to glycol chitosan polymers. The amphiphilic conjugates readily formed nanoparticle structure (average size = 302 ± 22 nm) in aqueous condition. Water-insoluble paclitaxel (PTX) was readily encapsulated into HO-CNPs with a high drug-loading amount up to 24.2 wt.% (2.4 fold higher than other polymeric nanoparticles) by a simple dialysis method. The PTX encapsulated HO-CNPs (PTX-HO-CNPs; average size = 343 ± 12 nm) were very stable in aqueous media up to 50 days. Also, PTX-HO-CNPs presented rapid cellular uptake and lower cytotoxicity in cell culture system, compared to Cremophor EL/ethanol formulation of PTX. In tumor-bearing mice, the extravasation and accumulation of PTX-HO-CNPs in tumor tissue were precisely observed by intravital fluorescence imaging techniques. Furthermore, PTX-HO-CNPs showed the higher therapeutic efficacy, compared to Abraxane®, a commercialized PTX-formulation. These overall results demonstrate its potential as a new nano-sized PTX carrier for cancer treatment.

Original languageEnglish
Pages (from-to)823-831
Number of pages9
JournalJournal of Controlled Release
Volume172
Issue number3
DOIs
Publication statusPublished - 2013 Nov 13

Fingerprint

Paclitaxel
Nanoparticles
Pharmaceutical Preparations
Neoplasms
Therapeutics
Drug Carriers
glycol-chitosan
Optical Imaging
Drug Delivery Systems
Solubility
Dialysis
Polymers
Ethanol
Cell Culture Techniques
Water

Keywords

  • Cancer therapy
  • Drug delivery
  • Glycol chitosan nanoparticles
  • Hydrotropic oligomer
  • Paclitaxel
  • Tumor-targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. / Koo, Heebeom; Min, Kyung Hyun; Lee, Sang Cheon; Park, Jae Hyung; Park, Kinam; Jeong, Seo Young; Choi, Kuiwon; Kwon, Ick Chan; Kim, Kwang Meyung.

In: Journal of Controlled Release, Vol. 172, No. 3, 13.11.2013, p. 823-831.

Research output: Contribution to journalArticle

Koo, Heebeom ; Min, Kyung Hyun ; Lee, Sang Cheon ; Park, Jae Hyung ; Park, Kinam ; Jeong, Seo Young ; Choi, Kuiwon ; Kwon, Ick Chan ; Kim, Kwang Meyung. / Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. In: Journal of Controlled Release. 2013 ; Vol. 172, No. 3. pp. 823-831.
@article{834a84beb9164402a1ad3b65461bc938,
title = "Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery",
abstract = "Enhanced drug-loading and therapeutic efficacies are highly essential properties for nanoparticles as tumor-targeting drug carriers. Herein, we developed the glycol chitosan nanoparticles with hydrotropic oligomers (HO-CNPs) as a new tumor targeting drug delivery system. For enhancing drug-loading efficiency of paclitaxel in drug carriers, hydrotropic 2-(4-(vinylbenzyloxy)-N, N-diethylnicotinamide) (VBODENA-COOH) oligomers, that were used for enhancing the aqueous solubility of paclitaxel, were directly conjugated to glycol chitosan polymers. The amphiphilic conjugates readily formed nanoparticle structure (average size = 302 ± 22 nm) in aqueous condition. Water-insoluble paclitaxel (PTX) was readily encapsulated into HO-CNPs with a high drug-loading amount up to 24.2 wt.{\%} (2.4 fold higher than other polymeric nanoparticles) by a simple dialysis method. The PTX encapsulated HO-CNPs (PTX-HO-CNPs; average size = 343 ± 12 nm) were very stable in aqueous media up to 50 days. Also, PTX-HO-CNPs presented rapid cellular uptake and lower cytotoxicity in cell culture system, compared to Cremophor EL/ethanol formulation of PTX. In tumor-bearing mice, the extravasation and accumulation of PTX-HO-CNPs in tumor tissue were precisely observed by intravital fluorescence imaging techniques. Furthermore, PTX-HO-CNPs showed the higher therapeutic efficacy, compared to Abraxane{\circledR}, a commercialized PTX-formulation. These overall results demonstrate its potential as a new nano-sized PTX carrier for cancer treatment.",
keywords = "Cancer therapy, Drug delivery, Glycol chitosan nanoparticles, Hydrotropic oligomer, Paclitaxel, Tumor-targeting",
author = "Heebeom Koo and Min, {Kyung Hyun} and Lee, {Sang Cheon} and Park, {Jae Hyung} and Kinam Park and Jeong, {Seo Young} and Kuiwon Choi and Kwon, {Ick Chan} and Kim, {Kwang Meyung}",
year = "2013",
month = "11",
day = "13",
doi = "10.1016/j.jconrel.2013.08.297",
language = "English",
volume = "172",
pages = "823--831",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery

AU - Koo, Heebeom

AU - Min, Kyung Hyun

AU - Lee, Sang Cheon

AU - Park, Jae Hyung

AU - Park, Kinam

AU - Jeong, Seo Young

AU - Choi, Kuiwon

AU - Kwon, Ick Chan

AU - Kim, Kwang Meyung

PY - 2013/11/13

Y1 - 2013/11/13

N2 - Enhanced drug-loading and therapeutic efficacies are highly essential properties for nanoparticles as tumor-targeting drug carriers. Herein, we developed the glycol chitosan nanoparticles with hydrotropic oligomers (HO-CNPs) as a new tumor targeting drug delivery system. For enhancing drug-loading efficiency of paclitaxel in drug carriers, hydrotropic 2-(4-(vinylbenzyloxy)-N, N-diethylnicotinamide) (VBODENA-COOH) oligomers, that were used for enhancing the aqueous solubility of paclitaxel, were directly conjugated to glycol chitosan polymers. The amphiphilic conjugates readily formed nanoparticle structure (average size = 302 ± 22 nm) in aqueous condition. Water-insoluble paclitaxel (PTX) was readily encapsulated into HO-CNPs with a high drug-loading amount up to 24.2 wt.% (2.4 fold higher than other polymeric nanoparticles) by a simple dialysis method. The PTX encapsulated HO-CNPs (PTX-HO-CNPs; average size = 343 ± 12 nm) were very stable in aqueous media up to 50 days. Also, PTX-HO-CNPs presented rapid cellular uptake and lower cytotoxicity in cell culture system, compared to Cremophor EL/ethanol formulation of PTX. In tumor-bearing mice, the extravasation and accumulation of PTX-HO-CNPs in tumor tissue were precisely observed by intravital fluorescence imaging techniques. Furthermore, PTX-HO-CNPs showed the higher therapeutic efficacy, compared to Abraxane®, a commercialized PTX-formulation. These overall results demonstrate its potential as a new nano-sized PTX carrier for cancer treatment.

AB - Enhanced drug-loading and therapeutic efficacies are highly essential properties for nanoparticles as tumor-targeting drug carriers. Herein, we developed the glycol chitosan nanoparticles with hydrotropic oligomers (HO-CNPs) as a new tumor targeting drug delivery system. For enhancing drug-loading efficiency of paclitaxel in drug carriers, hydrotropic 2-(4-(vinylbenzyloxy)-N, N-diethylnicotinamide) (VBODENA-COOH) oligomers, that were used for enhancing the aqueous solubility of paclitaxel, were directly conjugated to glycol chitosan polymers. The amphiphilic conjugates readily formed nanoparticle structure (average size = 302 ± 22 nm) in aqueous condition. Water-insoluble paclitaxel (PTX) was readily encapsulated into HO-CNPs with a high drug-loading amount up to 24.2 wt.% (2.4 fold higher than other polymeric nanoparticles) by a simple dialysis method. The PTX encapsulated HO-CNPs (PTX-HO-CNPs; average size = 343 ± 12 nm) were very stable in aqueous media up to 50 days. Also, PTX-HO-CNPs presented rapid cellular uptake and lower cytotoxicity in cell culture system, compared to Cremophor EL/ethanol formulation of PTX. In tumor-bearing mice, the extravasation and accumulation of PTX-HO-CNPs in tumor tissue were precisely observed by intravital fluorescence imaging techniques. Furthermore, PTX-HO-CNPs showed the higher therapeutic efficacy, compared to Abraxane®, a commercialized PTX-formulation. These overall results demonstrate its potential as a new nano-sized PTX carrier for cancer treatment.

KW - Cancer therapy

KW - Drug delivery

KW - Glycol chitosan nanoparticles

KW - Hydrotropic oligomer

KW - Paclitaxel

KW - Tumor-targeting

UR - http://www.scopus.com/inward/record.url?scp=84887132067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887132067&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2013.08.297

DO - 10.1016/j.jconrel.2013.08.297

M3 - Article

C2 - 24035978

AN - SCOPUS:84887132067

VL - 172

SP - 823

EP - 831

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -